Treating fungal infections is challenging due to the emergence of drug resistance and the limited number of clinically useful antifungal drugs. To improve clinical outcome it will be necessary to develop new antifungal drugs with different mechanisms of action and to discover drugs that improve the fungicidal activity of current antifungals. This study reveals a new role for fungal protein kinase C (PKC) signaling in resistance to drugs targeting the ergosterol biosynthesis pathway in the pathogenic fungus, Candida albicans, and the model yeast, Saccharomyces cerevisiae. PKC signaling enabled survival of antifungal-induced cell membrane stress in part through the mitogen-activated protein kinase (MAPK) cascade and through cross-talk with calcineurin signaling in both species. The molecular chaperone Hsp90, which stabilizes client proteins including calcineurin, also stabilized the terminal C. albicans MAPK, Mkc1. This establishes new circuitry connecting PKC with Hsp90 and calcineurin, and suggests that inhibiting fungal Pkc1 can be a promising strategy for treating life-threatening fungal infections.

Treating fungal infections is challenging due to the emergence of drug resistance and the limited number of clinically useful antifungal drugs. To improve clinical outcome it will be necessary to develop new antifungal drugs with different mechanisms of action and to discover drugs that improve the fungicidal activity of current antifungals. This study reveals a new role for fungal protein kinase C (PKC) signaling in resistance to drugs targeting the ergosterol biosynthesis pathway in the pathogenic fungus, Candida albicans, and the model yeast, Saccharomyces cerevisiae. PKC signaling enabled survival of antifungal-induced cell membrane stress in part through the mitogen-activated protein kinase (MAPK) cascade and through cross-talk with calcineurin signaling in both species. The molecular chaperone Hsp90, which stabilizes client proteins including calcineurin, also stabilized the terminal C. albicans MAPK, Mkc1. This establishes new circuitry connecting PKC with Hsp90 and calcineurin, and suggests that inhibiting fungal Pkc1 can be a promising strategy for treating life-threatening fungal infections.

Les résistances aux traitements actuels contre le cancer incitent à trouver de nouvelles cibles thérapeutiques. Une de ces cibles, la hsp90 (heat shock protein 90), impliquée dans la maturation de protéines clientes oncogènes, se révèle très prometteuse car son inhibition induit la dégradation de ces protéines par la voie du protéasome.PU3 et PU24S sont des inhibiteurs de la hsp90 de type purine fonctionnalisés en position 8. Dans le but d'identifier des composés encore plus actifs et/ou de nouvelles familles d'inhibiteurs, nous avons développé de nouveaux procédés sélectifs métallo-catalysés permettant l'activation de liaisons C-H de divers hétérocycles, et en particulier des purines (adénines, xanthines). Ces nouvelles approches ont permis un accès direct et simple à de nombreuses purines fonctionnalisées en C-8 par des groupements aromatiques, hetéroaromatiques, éthyléniques et benzyliques.

Heat shock protein 90 (Hsp90) is an essential and conserved chaperone, required for the conformational maturation and stability of many signaling kinases. We hypothesized that the functional pleiotropism of Hsp90 can be exploited during pharmacological inhibition causing simultaneous restraint of tumor growth as well as suppression of distant spread. Recognizing the lack of therapeutic options in advanced and metastatic squamous cell carcinomas (SCC) of the uterine cervix as well as the oral cavity, this dual concept was tested in corresponding cell lines and xenografts, and correlated with clinical data on client protein expression. Examination of the cell cycle response to Hsp90 inhibition revealed a G2/M-arrest in a panel of four cervical cancer cell lines and a contribution of abnormal mitosis to apoptosis induction in vitro. Although limited to intraperitoneal application, in vivo evidence of biological activity including heat shock response and decreased client kinase phosphorylation was seen with the geldanamycin derivative 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG). Importantly, focal adhesion kinase (FAK) signaling and associated functional parameters were inhibited by the drug treatment. Functional significance of FAK as a client was confirmed using a molecular model based on FAK-related non-kinase (FRNK) expression. Dependency on FAK appeared to be a requirement for full response to FRNK as well as 17-DMAG, and was observed in the mesenchymal-like cervical cell line SiHa. FAK expression and E-cadherin loss were features found in both cervical and oral malignancies, but absent from normal mucosa of either anatomic site. Particularly high FAK expression was noted in oral SCC with sarcomatoid features. Thus, we conclude that Hsp90 inhibition has potential in the treatment of advanced and metastatic SCC of cervical and oral origin. The further examination of novel Hsp90-targeting compounds as well as strategies focused on other components of the Hsp90 chaperone complex seems warranted.

Le Ca[indice supérieur 2+] joue un rôle primordial dans plusieurs processus physiologiques comme la contraction, la sécrétion, la croissance et la prolifération cellulaire et même l’apoptose. Ainsi, une régulation adéquate des niveaux de Ca[indice supérieur 2+] dans la cellule est essentielle à son bon fonctionnement. Plusieurs protéines-clés sont impliquées dans cette homéostasie calcique. Cette étude a permis d’identifier deux mécanismes distincts responsables de friner la signalisation calcique dans un modèle de cellules non-excitables et dans un modèle de cellules excitables, en mettant l’emphase sur la régulation des canaux calciques par leur interaction avec des protéines clés. Le premier mécanisme implique la régulation du récepteur à l’inositol 1,4,5-trisphosphate (IP[indice inférieur 3]R) par la protéine chaperonne Hsp90 dans les cellules HEK293T. J’ai montré que Hsp90 interagit avec l'IP[indice inférieur 3]R dans le but de diminuer son activité. De plus, cette interaction dépend de la voie de signalisation de l’insuline, plus particulièrement des protéines kinases mTOR et Src, qui sont impliquées dans cette interaction. Ainsi, l’interaction entre Hsp90 et l'IP[indice inférieur 3]R fait partie d’un mécanisme de rétroaction négative de la voie de signalisation de l’insuline. Le second mécanisme implique la régulation des canaux calciques dépendants du voltage de type T (T-VDCC) par la protéine STIM1 dans les cardiomyocytes HL-1. J'ai montré que STIM1, qui est le principal senseur de Ca[indice supérieur 2+] du réticulum sarco/endoplasmique, interagit avec les T-VDCC afin de diminuer leur expression à la membrane cellulaire et ainsi atténuer leur activité. Cette interaction permet de prévenir une entrée excessive de Ca[indice supérieur 2+] dans la cellule menant à une surcharge de Ca[indice supérieur 2+] dans le réticulum sarcoplasmique et, par le fait même, à des événements arythmiques associés à la surcharge. Bien que ces deux études aient été effectuées dans des environnements différents, soit un modèle de cellules non-excitables et un modèle de cellules excitables, elles mettent en évidence deux mécanismes pouvant friner la signalisation calcique dans le but d’assurer une fonction normale à la cellule.

This thesis focuses on the evaluation of biomarkers for radio-immunodiagnostics and radio-immunotherapy and on radiosensitization strategies after HSP90 inhibition, as a step towards more personalized cancer medicine. There is a need to develop new tracers that target cancer-specific biomarkers to improve diagnostic imaging, as well as to combine treatment strategies to potentiate synergistic effects. Special focus has been on the cell surface molecule CD44 and its oncogenic variants, which were found to exhibit unique expression patterns in head and neck squamous cell carcinoma (HNSCC). The variant CD44v6 seems to be a promising target, because it is overexpressed in this cancer type and is associated with radioresistance. Two new radioconjugates that target CD44v6, namely, the Fab fragment AbD15179 and the bivalent fragment AbD19384, were investigated with regard to specificity, biodistribution and imaging performance. Both conjugates were able to efficiently target CD44v6-positive tumors in vitro and in vivo. PET imaging of CD44v6 with 124I-AbD19384 revealed many advantages compared with the clinical standard 18F-FDG. Furthermore, the efficacy of the novel HSP90 inhibitor AT13387 and its potential use in combination with radiation treatment were evaluated. AT13387 proved to be a potent new cancer drug with favorable pharmacokinetics. Synergistic combination effects at clinically relevant drug and radiation doses are promising for both radiation dose reduction and minimization of side effects, or for an improved therapeutic response. The AT13387 investigation indicated that CD44v6 is not dependent on the molecular chaperone HSP90, and therefore, radio-immunotargeting of CD44v6 in combination with the HSP90 inhibitor AT13387 might potentiate treatment outcomes. However, EGFR expression levels did correlate with HSP90 inhibition, and therefore, molecular imaging of EGFR-positive tumors may be used to assess the treatment response to HSP90 inhibitors. In conclusion, these results demonstrate how tumor targeting with radiolabeled vectors and chemotherapeutic compounds can provide more specific and sensitive diagnostic tools and treatment options, which can lead to customized treatment decisions and a functional diagnosis that provides more precise and safer drug prescribing, as well as a more effective treatment for each patient.

No description available.

Thesis (Ph.D. in Toxicology) -- University of Colorado Denver, 2007. / Typescript. Includes bibliographical references (leaves 158-180). Free to UCD affiliates. Online version available via ProQuest Digital Dissertations;

Doctor of Philosophy / Department of Diagnostic Medicine/Pathobiology / Philip R. Hardwidge / Microbial pathogens have evolved secretion systems to deliver arsenals of virulence proteins (effectors) to disrupt host homeostasis and manipulate host immune defenses. The best-characterized system mediating effector delivery into host cells is type III secretion system (T3SS) expressed by Gram-negative bacteria, including enteric pathogens enteropathogenic/enterohemorrhagic Escherichia coli (EPEC/EHEC), Shigella, Yersinia, and Salmonella. Pathogen-host cell protein interactions within the host cell alter host cell signaling and ultimately subvert pathogen-induced inflammatory response. In the first project, we identified the Salmonella Secreted Effector L (SseL) that deubiquitinated ribosomal protein S3 (RPS3) to inhibit its nuclear translocation. RPS3 guides the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) subunits to specific B sites and plays an important role in the innate response to bacterial infection. Two E. coli effectors block RPS3 nuclear translocation. Non-locus-of-enterocyte-effacement (non-LEE) encoded effector NleH1 inhibits RPS3 phosphorylation by IKK-, an essential aspect of the RPS3 nuclear translocation process. NleC proteolysis of p65 generates an N-terminal p65 fragment that competes for full-length p65 binding to RPS3, thus also inhibiting RPS3 nuclear translocation. Thus, E. coli has multiple mechanisms by which to block RPS3-mediated transcriptional activation. With this in mind, we considered whether other enteric pathogens also encode T3SS effectors that impact this important host regulatory pathway. In this study, we report that SseL, which was previously shown to function as a deubiquitinase and inhibit NF-B signaling, also inhibits RPS3 nuclear translocation by deubiquitinating this important host transcriptional co-factor. RPS3 deubiquitination by SseL was restricted to K63-linkages and mutating the active-site cysteine of SseL abolished its ability to deubiquitinate and subsequently inhibit RPS3 nuclear translocation. Thus, Salmonella also encodes at least one T3SS effector that impacts RPS3 activities in the host nucleus. In the second project, we attempted to identify a cofactor involved in the interaction between E. coli effector NleH1 and host kinase the IB kinase- (IKK). The EHEC NleH1 effector inhibits NF-B pathway by reducing the nuclear translocation of RPS3. NleH1 prevents RPS3 phosphorylation by IKKIKK is a central kinase in the NF-B signaling pathway, yet the EHEC NleH1 effector only restricts the phosphorylation of a subset of the IKK substrates. We hypothesized that a protein cofactor might dictate the inhibitory specificity of NleH1 on IKK. We used mass spectrometry and determined that heat shock protein 90 (Hsp90) interacts with both NleH1 and IKK, and that inhibiting Hsp90 activity reduces RPS3 nuclear translocation. In the third project, we focused on the crystal structures of Salmonella secreted effector SseK1 and SseK2 from Salmonella typhimurium SL1344, and non-LEE encoded effector NleB2 from E. coli O145:H28 and propose catalytic residues for arginine glycosylation. Salmonella SseK1 and SseK2 are E. coli NleB1 orthologs that behave as NleB1-like glycosyltransferases, although they differ in protein substrate specificity. The bacterial effectors SseK and NleB1 glycosylate host cell death domain target proteins on arginine residues that inhibits death receptor signaling. We report crystal structures of SseK1, SseK2, and NleB2 and found they are highly similar to each other and comprises three domains including helix-loop-helix (HLH), lid, and catalytic domain. His-Glu-Asn (HEN) motif in the active site is essential for enzyme catalysis. We observe differences between SseK1 and SseK2 in interactions with substrates and identify substrate residues that are important for enzyme recognition.

Developing personalized cancer therapies based on cancer genomics methodologies forms the basis for future cancer therapeutics. A genomics platform was developed based on canine cancer to produce a proof-of-concept for personalized genomics led therapeutic choices but also developing personalized therapeutics for canine cancer patients themselves. The platform identified the genetic state of a canine cancer patient within two drugable pathways; p53 and HSP90/IRF1. The former gene was wild-type p53 thus directing the use of p53 activating molecules. The latter mutations in both HSP90 and IRF1 suggested an investigation into HSP90 and interferon signalling molecules as drug leads. Drugs that target both of these pathways were subsequently used to measure drug effects in cell line models but also to identify novel biomarkers of drug responses. My study focused on the effect of the HSP90-inhibitor Ganetespib had on its client proteins, particularly IRF-1. Briefly my results indicated the following:(i) Ganetespib downregulated IRF-1 protein levels in A375 cell lines and this attenuation was not mediated by either MDM2 or CHIP (E3 ligase). IFNγ- induced IRF-1 was also observed to be downregulated when Ganetespib was used in combination therapy.(ii) Insitu proximity ligation assay showed induced HSC70 upregulation upon HSP90 inhibition by Ganetespib and HSC70/MDM2 complexes were seen to be stabilized compared to the usage of MDM2/p53 inhibitor-nutlin. I hypothesize that MDM2/HSC70 complex might chaperon IRF-1 into lysosome for degradation via chaperon mediated autophagy pathway. (iii) My results also indicate that Ganetespib can downregulate IFN γ- induced PDL-1 expression in melanoma cell lines. Pre-sensitizing the cells with Ganetespib prior to the addition of IFNγ could attenuate PDL-1 to basal levels. (iv) My results also showed that the downregulation of PDL-1 by Ganetespib is an IRF-1 dependent mechanism. Therefore, my results suggest that HSP90 represents an important emerging target for cancer therapy because its inactivation results in the simultaneous blockade of multiple signalling pathways and can also sensitize tumor cells to other anticancer agents. Targeting HSP90 could also help to disrupt PD1/PDL- 1 interaction and activate immune system to recognise tumor cells. I conclude that HSP90 and IRF-1 play a critical role in types II interferon pathways and these findings establish a novel basis for the design of future Ganetespib-based combinatorial approaches to improve patient outcomes in this disease. These approaches finally demonstrate that cancer genomics can stratify choice of cancer drugs used on patients but also provide evidence that cancer patient samples can be used for the specific stratification of cancer drug choice based on cancer genomics data.